MedDataX Logo

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NCT ID: NCT02958358

Last Updated: 2016-11-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are doing this research study to find out how blood flow changes in the lungs of people with pulmonary hypertension before and after treatment with ambrisentan (sold under the brand name Letairis). The investigators hope that knowing about these differences will help us to better understand pulmonary hypertension and find new ways to diagnose it earlier.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall goal of this study is to evaluate lung, large vessel, and right ventricular glucose uptake rate using 18FDG PET and distribution of pulmonary perfusion using 13NN PET in patients with pulmonary hypertension before and after treatment with ambrisentan. The investigators propose a pilot study of patients with Group I PAH. The investigators plan to complete this pilot study with 5 patients (projected enrollment of 8 to allow for drop-out rate). Taken together, the studies above demonstrate that FDG-PET can be used to detect changes associated with PAH, and to monitor response to therapy. FDG-PET is a widely available technology, and is firmly established in the field of clinical oncology. Ambrisentan is an endothelin receptor antagonist that is FDA-approved to treat patients with pulmonary arterial hypertension. Patients will be eligible for participation in this study if they have already made a decision to start treatment with ambrisentan for pulmonary hypertension. The investigators propose a physiologic study of patients who will already have made a decision to start ambrisentan therapy. Participation in the study will not alter or affect participants decisions regarding treatment.

Prior human studies evaluating response to PH-specific therapies focused only on the right ventricle. Oikawa et al. looked at the RV uptake in patients with PH and evaluated them before and after treatment with epoprostenol. Fang and colleagues used FDG-SPECT evaluate FDG uptake in the RV of patients with IPAH and PH before and after treatment with sildenafil. Both of those studies used SUV (specific uptake variable). The investigators propose to focus on the lung and the RV uptake rate (Ki) in order to provide a more robust analysis of the metabolic changes that underlie the development of pulmonary hypertension both in the right ventricle and the lung parenchyma, and to study the response to ambrisentan with FDG-PET.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pulmonary hypertension ambrisentan PET imaging CT/PET

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Hypertension

Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan

Group Type EXPERIMENTAL

CT imaging, functional PET imaging

Intervention Type OTHER

Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CT imaging, functional PET imaging

Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is male or female aged \> or =18 years of age and \< or =70 years.
2. Subject is diagnosed with pulmonary arterial hypertension (WHO Group I, by right heart catheterization (RHC), mean PA pressure \> 25 and PCWP \< 15) and planning to start therapy with ambrisentan, either as de-novo monotherapy or as part of combination therapy.
3. Subject has most recently undergone RHC within three months of entering the study.
4. If patient has been on PAH-specific therapy, the therapy (agent and dose) has been unchanged for at least three months.
5. The subject is capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
6. A signed and dated written informed consent is obtained from the subject.
7. Available to complete the study.
8. Able to fast for 6 hours prior to the study.
9. Able to lie flat and able to perform a 30 second breath hold.

Exclusion Criteria

1. FEV1 and/or TLC \< 70% predicted.
2. PCWP \> 15 mm Hg.
3. Inability to perform the study (by primary MD or investigator assessment).
4. The subject is unable to perform the respiratory maneuvers necessary for the exam.
5. Subjects who have diabetes mellitus or glucose intolerance.
6. Subjects who have a known contraindication to ambrisentan.
7. Subjects who have a past or present disease, which as judged by the Investigators may affect the outcome of this study.
8. The subject has suspected history of drugs or alcohol abuse within the six months prior to the screening visit.
9. The subject is a woman of childbearing potential who is pregnant, seeking to become pregnant, or has a positive pregnancy test.
10. Subject with clinical instability in the judgment of the investigator, or hospitalization for progression of pulmonary hypertension or right heart failure in the three months prior to the study.
11. Subject with diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, allergic rhinitis, asthma, heart failure, ischemic heart disease, or COPD.
12. Subject that had a respiratory tract infection in the 4 weeks prior to the screening visit and throughout the duration of the study.
13. The subject has been exposed to a radiation dose over the past year that, when added to the radiation dose expected in this study, would exceed permissible yearly exposure as determined by the MGH radiation safety committee.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gilead Sciences

INDUSTRY

Sponsor Role collaborator

Robert Scott Harris, M.D.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert Scott Harris, M.D.

Associate Physician, Massachusetts General Hospital, Associate Professor, Harvard Medical School

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert S Harris, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013P002592

Identifier Type: -

Identifier Source: org_study_id